Tower Research Capital (TRC)’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
Other funds holding TRDA
BBA
Tower Research Capital (TRC)'s TRDA Position: Q3 2026 in Review
Tower Research Capital (TRC) reduced its Entrada Therapeutics (TRDA) stake by 55% in Q3 2026, selling an estimated $11.2K and leaving 1,302 shares worth $8.27K. The position accounts for ﹤0.01% of the portfolio, ranked #4416.
Tower Research Capital (TRC) first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $102K in Q3 2024. 132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.
- Tower Research Capital (TRC) held 1,302 shares of Entrada Therapeutics worth $8.27K as of Q3 2026.
- Tower Research Capital (TRC) sold 1,614 Entrada Therapeutics shares in Q3 2026, an estimated $11.2K.
- Entrada Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4416 holding.
- Tower Research Capital (TRC) first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
- Tower Research Capital (TRC)'s Entrada Therapeutics position peaked at $102K in Q3 2024.
- 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.